AI Article Synopsis
- Acute lung injury (ALI) is a complex disease caused by various factors, and the review discusses how it develops from different types of lung damage and its diverse underlying mechanisms.
- The review highlights the varied nature of ALI, covering its occurrence rates, symptoms, possible biomarkers, and genetic aspects, noting that there’s currently no approved medication for it.
- The paper also assesses the differences between human ALI and animal models, and explores ongoing research into advanced nanomedicines that could lead to effective treatments for ALI in the future.
Article Abstract
Acute lung injury (ALI) is a complex disease with numerous causes. This review begins with a discussion of disease development from direct or indirect pulmonary insults, as well as varied pathogenesis. The heterogeneous nature of ALI is then elaborated upon, including its epidemiology, clinical manifestations, potential biomarkers, and genetic contributions. Although no medication is currently approved for this devastating illness, supportive care and pharmacological intervention for ALI treatment are summarized, followed by an assessment of the pathophysiological gap between human ALI and animal models. Lastly, current research progress on advanced nanomedicines for ALI therapeutics in preclinical and clinical settings is reviewed, demonstrating new opportunities towards developing an effective treatment for ALI.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10768317 | PMC |
| http://dx.doi.org/10.1186/s12967-023-04828-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!